Biotech

All Articles

Lykos will certainly talk to FDA to reevaluate its decision complying with turndown of MDMA treatment for post-traumatic stress disorder

.Complying with an inadequate revealing for Lykos Therapeutics' MDMA applicant for trauma at a recen...

AN 2 halves head count, quits period 3 trial after information dissatisfy

.AN2 Rehabs is reassessing its own company in response to lackluster midphase information, promising...

Merck pays $700M for bispecific, spying autoimmune opening and possibility to test Amgen in cancer

.Merck &amp Co. is actually paying for $700 million upfront to challenge Amgen in a blood cancer cel...

Gilead pays J&ampJ $320M to go out licensing package for seladelpar

.With Gilead Sciences almost an FDA choice for its liver health condition drug seladelpar, the compa...

' All hands on deck' at Lilly as peers target excessive weight market

.Chief executive officer David Ricks can easily observe the business setting up tents at basecamp be...

Entero laying off team, abandoning office and stopping briefly R&ampD

.Bed mattress Liquidators has switched Entero Rehabs white as a piece. The creditor purchased Entero...

Exelixis goes down ADC after determining it's no suit for Tivdak

.Exelixis is losing hope on its own cells aspect (TF)- targeting antibody-drug conjugate after endin...

Relay loses interest in SHP2 prevention after Genentech leaves

.Three full weeks after Roche's Genentech unit bowed out an SHP2 inhibitor contract, Relay Rehab has...

Stoke's Dravet syndrome med launched of partial professional hold

.Stoke Rehabs' Dravet disorder drug has been actually devoid of a predisposed grip, removing the way...

Fierce Biotech's Gabrielle Masson presents Fierce 15 at NYSE

.Fierce Biotech Associate Editor Gabrielle Masson provided the 2024 course of Intense 15 victors on ...